Google capital injection instrumentation R & D and development of bio electronic devices

Galvani bio electronics headquarters will be located in the UK, GSK will hold 55% of the shares of the joint venture, Verily Life science companies (formerly known as Google Life science companies) will hold 45% of the shares. GSK said that the two parent companies will contribute to the existing intellectual property rights, and plans in the next seven years for the Galvani company to invest $700 million (about 540 million pounds), and complete the development of the company to develop a milepost -- develop biological electronic medical devices through regulatory approval.

Since 2012, GSK is active in the field of biological electron, GlaxoSmithKline believe that chronic diseases such as arthritis, diabetes and asthma, can be treated by electrical stimulation of the nerve pathway.

Galvani company's initial work will focus on the establishment of inflammation, metabolism, endocrine disorders, including type 2 diabetes patients, including clinical verification principles, while the development of relevant dimensions of small, high precision devices.

GlaxoSmithKline global vaccine company chairman MoncefSlaoui in determining GlaxoSmithKline on biological electronics investment has played an important role, he will serve as the new chairman of the company, he pointed out, "the signal control many reactions of the human body by the nervous system and the body organ that is released in many chronic diseases in telecommunications the number will become distorted. The goal of biological and electronic medicine is to interpret electrical signals by using the latest biological and technological techniques, to identify and correct the abnormal forms in the disease state by the micro devices attached to a single nerve. If successful, the method will become a new treatment with the same status as the traditional drug and vaccine therapy."

It is reported that the Galvani bio electronics company revenue will be fully integrated into the GlaxoSmithKline Co's financial statements, the GlaxoSmithKline Co will be headquartered in the R & D Center (located in Steve Ricci), at the same time in the Verily factory (in southern San Francisco) has second R & D center. The company plans to recruit about 30 professional scientists, engineers, and clinicians at the beginning of the program.